Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 4, 2010, Pages 243-249

  Bellmann, R ^a   Falkensammer, G ^b,c   Seger, C ^b   Weiler, S ^a   Kountchev, J ^a,d   Joannidis, M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GENERAL HOSPITAL   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Continuous renal replacement therapy; Drug monitoring; Glycopeptide antibiotics; Hemofilter clearance

Indexed keywords

TEICOPLANIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; FEMALE; HALF-LIFE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; TEICOPLANIN; YOUNG ADULT;

EID: 77950999156     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Dunzendorfer S, Wiedermann CJ. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous venovenous hemofiltration. Int J Clin Pharmacol Ther. 2002; 40: 142-149. (Pubitemid 34296381)
2. Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int. 1999; 72 (Suppl): 24-28.
3. Bouman CS, van Kan HJ, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med. 2006; 32: 2013-2019.
4. Del Favero A, Patoia L, Rosina R, Buniva G, Danese A, Bernareggi A, Molini E, Cavenaghi L. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother. 1991; 35: 2551-2557.
5. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother. 2005; 55 (Suppl): 5-13.
6. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs. 1985; 8: 307-312. (Pubitemid 16177849)
7. Hanada K, Ikari S, Koukaki Y, Utena A, Kimura T, Hamano K, Ariki H, Masuhara K, Ogata H. Comparison of pharmacokinetics of individual teicoplanin components in patients. Biol Pharm Bull. 2007; 30: 952-954. (Pubitemid 46708647)
8. Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000; 45: 835-841. (Pubitemid 30348955)
9. Hillaire-Buys D, Peyriere H, Lobjoie E, Bres J, Ossart M, Despaux E. Influence of arterio-venous haemofiltration on teicoplanin elimination. Br J Clin Pharmacol. 1995; 40: 95-97.
10. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol. 1996; 36: 1114-1119. (Pubitemid 27056938)
11. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit. 1998; 20: 473-477. (Pubitemid 28463435)
12. Meyer B, Ahmed el Gendy S, Delle Karth G, Locker GJ, Heinz G, Jaeger W, Thalhammer F. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res. 2003; 26: 135-140.
13. Meyer B, Traunmüller F, Hamwi A, Hollenstein UM, Locker GJ, Sperr WR, Staudinger T, Thalhammer- Scherrer R, Burgmann H, Thalhammer F. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol. 2004; 42: 556-5560. (Pubitemid 39386796)
14. Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, Debaene B, Couet W. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006; 32: 775-779.
15. Pea F, Brollo L, Lugano M, Dal Pos L, Furlanut M. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2001; 23: 587-588. (Pubitemid 32912282)
16. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003; 51: 971-975. (Pubitemid 36503431)
17. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007; 46: 997-1038. (Pubitemid 350136909)
18. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995; 21: 612-620.
19. Targocid® (teicoplanin) package insert. Sanofi Aventis, Vienna, Austria, 2003.
20. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000; 39: 167-183.
21. Wolter K, Claus M, Fritschka E. Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD) Eur J Clin Pharmacol. 1994; 46: 179-180. (Pubitemid 24101340)
22. Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K. Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med. 2003; 29: 2094-2095. (Pubitemid 37487148)
23. Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, Masada M. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007; 29: 399-403. (Pubitemid 47220455)